属于药物所药理室陈晓光课题组。目前本组共有8个职工，其中博士生导师一人，硕士生导师三人。实验室共有学生15-20人。课题组的特色和专长就是小分子抗肿瘤药物和自身免疫性疾病的药物研发。本课题组科研、学习、生活的氛围较为和谐。

纵向项目：已完成科研项目3项，在研科研项目2项。

横向项目：作为药理学科实验的负责人全程参与1类新药艾姆地芬的临床前药理实验和临床报批工作，目前此项目已经成功转让于企业，并获得CFDA临床试验批准开展I期临床试验。

本人主持过3个科研项目。包括一个国家自然科学基金的青年基金，一个所级项目和一个院校级项目。另外本人还作为重大项目的子任务负责人，参与了十三五创新药物重大专项和创新工程-协同创新项目。

发表一作或通讯作者文章17篇。代表作如下

[1] K. Zhang, F.Lai*, S.Lin, M. Ji, H. Tian, N. Xue, L.Sheng, X. Zou, Y. Li, X. Chen, H. Xu, Design, Synthesis, and BiologicalEvaluation of 4-Methyl QuinazolineDerivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide3-Kinases and Histone Deacetylases, J Med Chem, 62 (2019) 6992-7014.(IF:6.054)

[2] N. Xue, F. Lai*, T. Du, S. Zhang, X. Yu, J. Jin, X.Chen, Chaperone-mediated autophagy degradation of IGF-1Rbeta induced byNVP-AUY922 in pancreatic cancer, Cell Mol Life Sci, 76 (2019) 3433-3447.(IF:7.014)

[3] J. Jin, M. Ji, R. Fu, Q.Xiao, J. Hu, X. Wang, F. Lai*, D. Yin, X. Chen, Sphingosine-1-PhosphateReceptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- andCollagen-Induced Arthritis, Front Pharmacol, 10 (2019) 1085.(IF:4.225)

[4] Q. Zhang, S. Xu, F.Lai*, Y.Wang, N. Zhang, M. Nazare,H.Y. Hu, Rapid Synthesis of gamma-Halide/Pseudohalide-SubstitutedCyanine Sensors with Programmed Generation of Singlet Oxygen, Org Lett, 21(2019) 2121-2125.(IF:6.492)

[5] C. Zhou, F.Lai*, L.Sheng, X. Chen, Y. Li, Z. Feng, Design, Synthesis and Biological Evaluation ofPhenyl Urea Derivatives as IDO1 Inhibitors, Molecules, 25 (2020).(IF:3.267)

6] Y. Zang F. Lai*, K. Liu, T. Zhang, X. Chen, D. Zhang,Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatoryagents: Design, synthesis, biological evaluation, and nitric oxide releasestudies, Eur JMed Chem, 190(2020) 112079.(IF:5.572)

[7] G. Cui, F.Lai*, X.Wang, X. Chen, B. Xu, Design, synthesis and biological evaluation ofindole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors, Eur JMed Chem, 188(2020) 111985.(IF:5.572)

[8] Y. He, J. Wen, Q. Cui, F.Lai*, D.Yin, H. Cui, Quantitative Evaluation of in Vivo Target Efficacy of Anti-tumorAgents via an Immunofluorescence and EdU Labeling Strategy, Front Pharmacol, 9(2018) 812.(IF:3.845)

 [9] H.Wen, Y. Liu, S. Wang, T. Wang, G. Zhang, X. Chen, Y. Li, H. Cui, F.Lai*, L.Sheng, Design and Synthesis of Indoleamine2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents,Molecules, 24 (2019).(IF:3.267)

[10] F.Lai*, N.Madan*, Q.Ye, Q. Duan, Z.Li, S. Wang, S. Si, Z. Xie,Identification of a mutant alpha1 Na/K-ATPase that pumps but is defective insignal transduction, J Biol Chem, 288(2013) 13295-13304. (IF:4.599)

[11] Q. Ye*, F.Lai*, M.Banerjee, Q. Duan, Z.Li, S. Si, Z. Xie,Expression of mutant alpha1 Na/K-ATPase defective in conformational transitionattenuates Src-mediatedsignal transduction, J Biol Chem, 288(2013) 5803-5814. (IF:4.599)

[12] F. Lai*, Q.Liu, X. Liu, M. Ji, P. Xie, X.Chen, LXY6090 - a novel manassantin Aderivative - limits breast cancer growth through hypoxia-inducible factor-1inhibition, OncoTargets Ther, 9(2016) 3829-3840.(IF:2.3184)

[13] F. Lai*, Z. Shen*, H.Wen, J. Chen, X. Zhang, P. Lin, D. Yin, H. Cui, X. Chen, A Morphologicalidentification cell cytotoxicity assay using cytoplasm-localized fluorescentprobe (CLFP) to distinguish living and dead cells, Biochem Biophys Res Commun, 482(2017) 257-263.(IF:2.4680)

参与专利申请10余项，举例如下：

1、司书毅，许艳妮，刘祺，蒋建东，洪斌，李卓荣，姜威，贺晓波，徐扬，李永臻，来芳芳，巫晔翔，李霓，王智敏，刘伟，吴茱萸次碱类化合物的新用途，授权日期2012.9.26，授权号CN201110067053.1

2、司书毅，张忠兵，刘继开，许艳妮，谢子建，洪斌，姜威，李卓荣，王智敏，来芳芳，刘伟，冯婷婷，人ATP结合盒转运体A1活性调节剂筛选模型及其应用，授权日期2012.10.3，授权号CN201110074634.8

3、冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。苄苯醚类衍生物、及其制法和药物组合物与用途。申请日期：2017.05.23，申请号：PCT/CN2017/085417。

4、冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。烟醇醚类衍生物、及其制法和药物组合物与用途。申请日期：2017.05.23，申请号：PCT/CN2017/085418。

5、冯志强,陈晓光,张莉婧,杨阳,来芳芳,季鸣,周川,郑义,薛妮娜,李凌。溴代苄醚衍生物、及其制法和药物组合物与用途。申请日期：2017.05.23，申请号：PCT/CN2017/085419。

6、冯志强,陈晓光,杨阳,周川,来芳芳,季鸣,金小锋,薛妮娜,郑义,陈浩,李凌。苯醚类衍生物、及其制法和药物组合物与用途。申请日期：2017.05.23，申请号：PCT/CN2017/085420。